Systematic Evaluation of Cloudman S91 and YUMM1.7 Murine Melanoma Models to Immunotherapy and Focal Radiation

AACR 2022 -- In the preclinical oncology setting, the B16-F10 syngeneic melanoma model is commonly used but is highly refractory to most immunomodulators, limiting the applicability of this model. To expand our offerings of melanoma models beyond B16-F10, we have characterized two syngeneic melanoma models, Cloudman S91 and YUMM1.7, for preclinical oncology studies. The two models were evaluated for their responses to immune modulatory agents and focal radiation in combination by tumor progression as well as evaluating changes in the tumor microenvironment by flow cytometry and gene expression analysis by Nanostring.

Copy and paste this URL:

https://biopharma.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/posters/UrsAACR22-2799-Murine-Melanoma.pdf